Please login to the form below

Not currently logged in
Email:
Password:

Pomalidomide Celgene

This page shows the latest Pomalidomide Celgene news and features for those working in and with pharma, biotech and healthcare.

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

The 750-patrient ELOQUENT-1 trial showed that adding Empliciti (elotuzumab) to background treatment with BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone didn’t extend the time patients with newly-diagnosed ... Celgene’s Pomalyst/Innovid

Latest news

  • FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

    The study participants had on average received seven earlier lines of therapy, including an immuno-modulatory drug such as Celgene’s Revlimid (lenalidomide), a proteasome inhibitor such as Takeda’s Velcade ... The company is at the planning stages

  • GSK preps filings for BCMA-targeting multiple myeloma drug GSK preps filings for BCMA-targeting multiple myeloma drug

    It is the most advanced BCMA-targeting ADC in development, with candidates from AstraZeneca (MEDI2228) and Celgene/Sutro Biopharma (CC-99712) still in early-stage development. ... The company is also at the planning stages for a phase 3 trial of the drug

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    Squibb got the go-ahead for Empliciti (elotuzumab) alongside Celgene’s Pomalyst (pomalidomide) and dexamethasone for relapsed/refractory multiple myeloma, based on the ELOQUENT-3 trial.

  • FDA verdict on Sanofi’s Darzalex rival is due in April 2020 FDA verdict on Sanofi’s Darzalex rival is due in April 2020

    prolong progression-free survival (PFS) when added to a standard myeloma regimen of Celgene’s Pomalyst/Imnovid (pomalidomide) and low-dose dexamethasone. ... Empliciti picked up an additional approval from the FDA as a third-line therapy for myeloma in

  • Janssen looks to expand Darzalex in Europe Janssen looks to expand Darzalex in Europe

    Regimen reduced risk of disease progression or death by 44%. Janssen is looking to broaden the use of its multiple myeloma blockbuster Darzalex, this time combining it with Celgene’s Revlimid ... Sanofi also has a promising CD38-targeting antibody for

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics